Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe optimal initial treatment strategies for CML
- Explain options for management of patients who are initially intolerant of standard imatinib first-line therapy
- Describe optimal treatment approaches to patient who experience hematologic relapse following first-line imatinib therapy
Test your ability to make optimal treatment decisions using patient histories and diagnostic information and see the case unfold according to your choices. Compare your answers with your peers and our expert faculty’s recommendations, and then review the supporting data.